KMPH KemPharm Inc.

+0.05  (+2%)
Previous Close 2.1
Open 2.1
Price To Book -0.6
Market Cap 56879007
Shares 26,455,352
Volume 76,514
Short Ratio
Av. Daily Volume 130,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 complete. NDA filing due 2019.
KP511/IR 511/ER
Severe pain
Phase 1 trial completed. Further trials to commence 1H 2017, with data end of 2017. NDA filing 2018.
Acute pain
Top-line data released July 9, 2018 - primary endpoint met. NDA filing due 1Q 2019.
CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018.
Apadaz (KP201/APAP)
Acute pain
Pivotal trial to be initiated 2019 with data also due in 2019.

Latest News

  1. KemPharm to Report Fourth Quarter and Year End 2018 Results
  2. KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
  3. What You Must Know About KemPharm, Inc.’s (NASDAQ:KMPH) Beta Value
  4. KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting
  5. KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
  6. New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production
  7. KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio
  8. KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
  9. KemPharm Webcast on Now Available for On-Demand Viewing
  10. Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
  11. KemPharm to Webcast Live at on December 6th
  12. What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?
  13. Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT